uniQure N.V.QUREEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.
QURE Q4 FY2025 Key Financial Metrics
Revenue
$5.6M
Gross Profit
$5.1M
Operating Profit
N/A
Net Profit
N/A
Gross Margin
92.2%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
6.6%
uniQure N.V. Q4 FY2025 Financial Summary
uniQure N.V. reported revenue of $5.6M (up 6.6% YoY) for Q4 FY2025, with a net profit of N/A (up 49.4% YoY) (N/A margin). Cost of goods sold was $435.0K.
Key Financial Metrics
| Total Revenue | $5.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 92.2% |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
uniQure N.V. Annual Revenue by Year
uniQure N.V. annual revenue history includes year-by-year totals (for example, 2025 revenue was $16.1M).
uniQure N.V. Quarterly Revenue & Net Profit History
uniQure N.V. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $5.6M | +6.6% | N/A | N/A |
| Q3 FY2025 | $3.7M | +61.8% | $-80.5M | -2175.9% |
| Q2 FY2025 | $5.3M | -52.7% | $-37.7M | -716.8% |
| Q1 FY2025 | $1.6M | -81.5% | $-43.6M | -2784.7% |
| Q4 FY2024 | $5.2M | -21.9% | N/A | N/A |
| Q3 FY2024 | $2.3M | +62.5% | $-44.4M | -1940.4% |
| Q2 FY2024 | $11.1M | +359.4% | $-56.3M | -506.0% |
| Q1 FY2024 | $8.5M | +59.3% | $-65.6M | -773.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M | $11.1M | $2.3M | $5.2M | $1.6M | $5.3M | $3.7M | $5.6M |
| YoY Growth | 59.3% | 359.4% | 62.5% | -21.9% | -81.5% | -52.7% | 61.8% | 6.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $770.0M | $730.8M | $645.8M | $556.5M | $605.4M | $584.9M | $888.4M | $824.9M |
| Liabilities | $623.3M | $633.7M | $590.0M | $563.3M | $571.7M | $588.9M | $659.6M | $626.0M |
| Equity | $146.8M | $97.1M | $55.8M | $-6.8M | $33.7M | $-4.0M | $228.7M | $198.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-60.6M | $-32.7M | $-36.6M | $-182.7M | $-44.1M | $-39.9M | $-16.4M | $-178.0M |